SGLT2 inhibitors and cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease: A real-world retrospective cohort study
The American Journal of Medicine
•
January 01, 2026
SGLT2 inhibitors linked to fewer cardio-hepatic events
In adults with metabolic dysfunction–associated steatotic liver disease, sodium-glucose cotransporter-2 inhibitors were associated with lower death, hospital stays, heart events, and liver complications. *Retrospective matched cohort study; Level 2b (OCEBM).
- Level of evidence
- Level 2b (OCEBM)
- DocG quality score
- 7.2 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
